Show simple item record

dc.creatorBraude, Philip
dc.creatorCarter, Ben
dc.creatorShort, Roxanna
dc.creatorVilches-Moraga, Arturo
dc.creatorVerduri, Alessia
dc.creatorLyndsay Pearce, Miss
dc.creatorPrice, Miss Angeline
dc.creatorQuinn, Terence J.
dc.creatorStechman, Michael
dc.creatorCollins, Jemima
dc.creatorBruce, Eilidh
dc.creatorEinarsson, Alice
dc.creatorRickard, Frances
dc.creatorMitchell, Emma
dc.creatorHolloway, Mark
dc.creatorHesford, James
dc.creatorBarlow Pay, Fenella
dc.creatorClini, Enrico
dc.creatorMyint, Phyo Kyaw
dc.creatorMoug, Susan
dc.creatorMcCarthy, Kathryn
dc.creatorHewitt, Jonathan
dc.date.accessioned2020-10-16T16:10:54Z
dc.date.available2020-10-16T16:10:54Z
dc.date.created2020
dc.identifier.issn2352-9067spa
dc.identifier.otherhttps://doi.org/10.1016/j.ijcha.2020.100660spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/14501
dc.description.abstractDuring the COVID-19 pandemic the continuation or cessation of angiotensinconverting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) has been contentious. Mechanisms have been proposed for both beneficial and detrimental effects. Recent studies have focused on mortality with no literature having examined length of hospital stay. The aim of this study was to determine the influence of ACEi and ARBs on COVID-19 mortality and length of hospital stay. Methods COPE (COVID-19 in Older People) is a multicenter observational study including adults of all ages admitted with either laboratory or clinically confirmed COVID-19. Routinely generated hospital data were collected. Primary outcome: mortality; secondary outcomes: Day-7 mortality and length of hospital stay. A mixed-effects multivariable Cox’s proportional baseline hazards model and logistic equivalent were used. Results 1371 patients were included from eleven centres between 27th February to 25th April 2020. Median age was 74 years [IQR 61-83]. 28.6% of patients were taking an ACEi or ARB. There was no effect of ACEi or ARB on inpatient mortality (aHR=0.85, 95%CI 0.65-1.11). For those prescribed an ACEi or ARB, hospital stay was 6 significantly reduced (aHR=1.25, 95%CI 1.02-1.54, p=0.03) and in those with hypertension the effect was stronger (aHR=1.39, 95%CI 1.09-1.77, p=0.007). Conclusions Patients and clinicians can be reassured that prescription of an ACEi or ARB at the time of COVID-19 diagnosis is not harmful. The benefit of prescription of an ACEi or ARB in reducing hospital stay is a new findingspa
dc.format.extent31 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherIJC Heart & Vasculaturespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCoronavirusspa
dc.subjectAngiotensin Receptor Antagonistsspa
dc.subjectAngiotensin-Converting Enzyme Inhibitorsspa
dc.subjectHospitalizationspa
dc.subjectHospital Mortalityspa
dc.titleThe influence of ACE inhibitors and ARBs on hospital length of stay and sur- vival in people with COVID-19spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.ijcha.2020.100660spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record